iRegene Therapeutics
Wuhan, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $42M
Overview
A biotech company developing iPSC-based cell therapies for neurological and retinal diseases using an AI-integrated discovery platform.
OphthalmologyNeurology
Technology Platform
An integrated AI-powered R&D ecosystem (iReMeta) for omics analysis and discovery, supporting the development of iPSC-based cell therapies and exosome delivery systems.
Opportunities
Large unmet medical need in neurodegenerative diseases (Parkinson's, MSA) and retinal degeneration; first-mover potential with iPSC therapies that have gained significant FDA regulatory designations (RMAT, FTD, ODD).
Risk Factors
High clinical development risk inherent in novel iPSC-based cell therapies; complex manufacturing and scalability challenges; competitive landscape in neurology and gene therapy.
Competitive Landscape
Competes with other iPSC-focused biotechs (e.g., BlueRock Therapeutics, Aspen Neuroscience) and gene therapy companies in ophthalmology; differentiated by its integrated AI platform and advanced clinical progress in Parkinson's and MSA with regulatory endorsements.